^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    06/21/2022
    Excerpt:
    HER2-Negative Regimens...Regimen added...Fam-trastuzumab deruxtecan-nxki (for HER2 IHC 1+ or 2+/ISH negative)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase 2, Open label Study of DS-8201a, an Anti-HER2-AntIbody Drug Conjugate (ADC) for advanced BreaSt Cancer patients, with biomarkers analysis to characterize response/resistance to therapY

    Excerpt:
    ...• Patient with HER2 negative (IHC0, 1+, and 2+/ISH-) and hormone receptor positive (ER+ and/or PR+) tumor must be resistant to endocrine therapy and CDK4/6 inhibitors, and must have been treated with capecitabine. ...
    Trial ID:
    2018-004868-57
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

    Excerpt:
    ...- Patient with HER2 negative (IHC0, 1+, and 2+/ISH-) and hormone receptor positive (estrogen receptor (ER)+ and/or progesterone receptor (PR)+) tumor must be resistant to endocrine therapy and CDK4/6 inhibitors, and must have been treated with capecitabine....
    Trial ID:
    DAISY